Knight Therapeutics Inc.

TSX:GUD.TO

Drug Manufacturers - Specialty & Generic

Healthcare
$11.56 +0.75%

+$0.07 today

Market cap
$1.14B
Beta
0.07
P/E (TTM)
164.6
EPS (TTM)
$0.06
52W Low $5.66High $9.59

Volume 0.04M

Average 0.10M

GUD.TO Other Working Capital

Cash effect of changes in other operating assets and liabilities.

Knight Therapeutics Inc.TSX: GUD.TO

Other Working Capital · Q1 FY2026 · quarter ended Mar 2026

Other working capital grows, but more slowly than its trailing trend

Q1 FY2026 other working capital of CA$2.68M rose 79.6% year over year, behind the +265.5% change in trailing-twelve-month other working capital. Sequentially, it fell 43.8% from the prior quarter.

Context

  • Other working capital amounted to 0.9% of revenue in FY2025, down 0.2 pp from a year earlier.
  • Other working capital increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +79.6% toward the trailing-twelve-month pace of +265.5%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
CA$2.68M-43.8% QoQ
Last fiscal yearDec 2025
CA$4.14M+202.1% YoY
LTMMar 2026
CA$5.33M+265.5% YoY
Other Working Capital past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+79.6%——
1 year+202.1%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Working Capital history

CAD · from the cash flow

Latest · FY2025
4.14M CAD
Year-over-year change
+202.1%

Other Working Capital vs competitors

How GUD.TO compares with its peers on the latest reported figures

  • Peers report in different currencies, so other working capital is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +265.5% is the highest of 8, against a peer median of +81.3%.
  • Other working capital amounts to 1.0% of revenue for GUD.TO, versus a peer median of 3.5%.
GUD.TO Competitors
Other Working Capital for GUD.TO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ACB.TOAurora Cannabis Inc.LTM Mar 2026CA$34.56M CAD-776.6%-49.5%10.9%
TSND.TOTerrAscend Corp.LTM Mar 2026$19.02M USD-40.3%+21.5%7.3%
WEED.TOCanopy Growth CorporationLTM Mar 2026CA$11M CAD+163.6%-2.0%3.5%
OGI.TOOrganiGram Holdings Inc.LTM Mar 2026CA$9.51M CAD+221.3%—3.5%
KSI.TOKneat.com, Inc.LTM Mar 2026CA$7.95M CAD+81.3%—11.9%
GUD.TOKnight Therapeutics Inc.LTM Mar 2026CA$5.33M CAD+265.5%—1.0%
CPH.TOCipher Pharmaceuticals Inc.LTM Mar 2026$1.39M USD-87.8%—2.7%
VHI.TOVitalhub Corp.LTM Mar 2026CA$1.06M CAD+118.2%—0.9%
Peer median (excluding GUD.TO) —+81.3%-2.0%3.5%

Competitors are the stored peer set for GUD.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

CAD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income15.68M(29.89M)(16.84M)4.33M(5.37M)
Depreciation & Amortization47.92M62.62M50.4M53.11M56.57M
Deferred Income Tax(7.64M)(17.13M)(9.13M)(3.24M)(3.81M)
Stock-Based Compensation3.05M1.89M2.33M1.86M8.11M
Change in Working Capital627K(9.99M)(28.01M)(19.62M)1.89M
Accounts Receivables8.59M(26.42M)5.58M(10.29M)(26.53M)
Inventory(17.19M)(11.43M)698K(5.91M)(17.82M)
Accounts Payables11.46M30.6M(21.63M)632K42.11M
Other Working Capital(2.23M)(2.74M)(12.66M)(4.06M)4.14M
Other Non-Cash Items(15.01M)32.98M37.19M(154K)12.91M
Operating Cash Flow44.62M40.48M35.94M36.28M70.3M
Capital Expenditures(224.18M)(25.82M)(9.96M)(31.47M)(1.91M)
Acquisitions (Net)(220.35M)000(110.05M)
Purchases of Investments(64.32M)(185.47M)(334.16M)(162.57M)(70.39M)
Sales of Investments180.54M150.54M345.47M196.12M112.43M
Other Investing Activities223.04M(2.33M)18.99M(14.12M)17.6M
Investing Cash Flow(105.28M)(63.08M)29.34M16.96M(84.11M)
Debt Repayment(14.19M)31.49M(18.02M)(18.05M)23.19M
Common Stock Issued0000511K
Common Stock Repurchased(64.42M)(30.07M)(53.48M)(8.87M)(6.35M)
Dividends Paid00000
Other Financing Activities297K(4.18M)(9.5M)(6.62M)(4.34M)
Financing Cash Flow(78.31M)1.76M(81M)(33.54M)13.01M
Effect of Forex Changes(4.66M)6.55M2.8M1.64M(2.86M)
Net Change in Cash(143.63M)(14.28M)(12.92M)21.35M(3.66M)
Free Cash Flow(179.57M)14.67M25.98M4.81M68.4M

Knight Therapeutics Inc.

TSX:GUD.TO

Intrinsic Alpha fair value

Locked

Current Price

$11.56

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.